|
Thailand Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Thailand Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Thailand.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Thai pharmaceutical and healthcare industry.
Competitive intelligence, Thai pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Thai market.
The Thailand Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Thailand Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Thai pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Thailand to test other views – a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Thai Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
- Exploit The Latest Competitive Thai Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Thailand.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Thailand Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Thailand Pharmaceutical And Healthcare Industry SWOT |
| Thailand Political SWOT |
| Thailand Economic SWOT |
| Thailand Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Business Environment Rankings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Thailand – Market Summary |
| Regulatory Regime |
| National Health Assembly Agenda Items |
| Intellectual Property Regime |
| IP Shortcomings |
| Counterfeit Drugs |
| Compulsory Licensing Regulatory Developments |
| Recent IP Developments |
| Pricing And Reimbursement |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Healthcare System |
| Healthcare Financing |
| Medical Tourism |
| Pharmaceutical Sector |
| Local Producers |
| Foreign Companies |
| Recent Industry Developments |
| Traditional Medicines |
| Pharmaceutical Retail |
| Vaccine Sector |
| Recent Vaccines Sector Developments |
| Research And Development |
| Recent Research And Development Activities |
| Biosimilars |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Thailand – Pharmaceutical Market Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Thailand – Healthcare Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Thailand – Economic Activity |
| Prescription Market Forecast |
| Table: Thailand – Prescription Market Indicators, Historical Data And Forecast (THBmn unless otherwise indicated) |
| Patented Drug Market Forecasts |
| Table: Thailand – Patented Market Indicators, 2003-2013 |
| Generics Market Forecasts |
| Table: Thailand – Generics Market Indicators, 2003-2013 |
| OTC Market Forecast |
| Table: Thailand – OTC Market Indicators, 2003-2013 (THBmn unless otherwise indicated) |
| Export/Import Forecasts |
| Table: Thailand – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Medical Device Market Forecast |
| Table: Thailand – Medical Device Market Indicators,2006-2013 (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Thailand – Other Health Indicators, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Thailand's Pharmaceutical Market In Q406 (most recent publically available data) |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| Pfizer |
| Sanofi-Aventis |
| Novartis |
| GlaxoSmithKline |
| Merck & Co |
| Domestic Manufacturer Profiles |
| Siam Pharmaceutical |
| Government Pharmaceutical Organisation (GPO) |
| Biolab Co |
| Thai Meiji Pharmaceutical Co |
Chapter - Country Snapshot: Thailand Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Non-Agricultural Wages, 2001-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Thailand Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Pharmaceutical Environment Ranking table for Q209, Thailand is found in 10th position, out of the 15 key markets surveyed in Asia Pacific. Thailand’s attraction for foreign drugmakers is largely based on its growing and ageing population, although its forecast compound annual growth rate (CAGR) of 6.89% (in local currency terms) in the 2008-2013 period is lower than for the Philippines, for example, which is placed 11th in the BMI matrix. Other drawbacks include unresolved political issues and the controversial compulsory licensing scheme, as well as a deteriorating economic situation. Overall, the value of the Thai pharmaceutical market, estimated at THB116.11bn (US$3.40bn) in 2008, is expected to top THB161.99bn (US$5.59bn) in 2013, although the need to ensure universal healthcare coverage will continue to threaten prices, as will the new health economics requirements for patented medicines.
In terms of notable company news, in February 2009 the Thai pharmaceutical regulator certified the quality of a generic version of a heart drug, clopidogrel, which is manufactured by an unnamed Indian supplier. The generic product is much cheaper than its patented alternative, Sanofi-Aventis’ Plavix (clopidogrel bisulfate), which had raised doubt about its efficacy. The certification will go some way towards increasing the public acceptance of generics, and also provide support for the compulsory licensing scheme. The product is imported by the Government Pharmaceutical Organisation (GPO), although the patented medicine has yet to be officially brought under the scheme.
Cost-containment pressures are also heralding problems for UK and US-based multinationals, respectively - GlaxoSmithKline (GSK) and Merck & Co - following the news that Thailand is planning to develop a generic version of a cervical cancer vaccine. While the launch of the product is far from imminent, it could potentially reach the market before 2017, when the first patent on the vaccine expires. Additionally, although Thailand has the second-highest cervical cancer prevalence in the region, public programmes for cervical cancer prevention are in their infancy. Nevertheless, the pending competition to GSK's Cervarix or Merck & Co's Gardasil could have a wider international impact, spurring on generic developers elsewhere.
In the meantime, given Thailand's disproportionate dependence on exports, we have a hard time envisaging anything but further weakness for the Thai baht and would not be surprised to see the currency rendezvous with its 2008 lows over the coming months. As evidenced by the intervention seen in recent weeks, the central bank - and the rest of the region for that matter - is reluctant to see any appreciation. With imported inflation now a non-issue and local industries tottering amid the brutal collapse in external demand, the internal pressure to nudge its currencies lower is increasing. Although the falls are unlikely to be as precipitous and disorderly as during the Asian financial crisis - when the causal dynamics were of a different nature altogether - some fairly large, albeit controlled, drops could materialise nonetheless, which would have a negative impact on CAGR rates of the Thai pharmaceutical market, as well as its overall values.
|
Thailand Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |